Stock comparison
Exelixis
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EXEL
Exelixis
Market cap
$12.61B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
Exelixis EXEL
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EXEL | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 71B | UTHR |
| Benjamin Graham | 74B | 76B | UTHR |
| Philip Fisher | 74B | 76B | UTHR |
| Peter Lynch | 58C | 62C | UTHR |
| Joel Greenblatt | 60C | 46D | EXEL |
| Charlie Munger | 71B | 64C | EXEL |
| Terry Smith | 80A | 64C | EXEL |
Side-by-side metrics
| Metric | EXEL | UTHR |
|---|---|---|
| Market cap | $12.61B | $24.13B |
| P/E (TTM) | 15.3x | 19.2x |
| EV/EBIT | 14.2x | 15.2x |
| ROIC (TTM) | 35.01% | 18.81% |
| Gross margin | 96.44% | 86.58% |
| Net margin | 35.08% | 40.61% |
| Revenue CAGR 5y | 12.76% | 17.22% |
| EPS CAGR 5y | 40.93% | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EXEL leads on
- ROIC (TTM)35.01%vs 18.81%+46%
- EPS CAGR 5y40.93%vs 29.84%+27%
- P/E (TTM)15.3xvs 19.2x+20%
- Gross margin96.44%vs 86.58%+10%
UTHR leads on
- Debt / Equity-vs 0.1x+100%
- Market cap$24.13Bvs $12.61B+48%
- Revenue CAGR 5y17.22%vs 12.76%+26%
- Net margin40.61%vs 35.08%+14%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.